Novartis presents oncology research advances with new data on Zykadia(TM ...
The Novartis data include new analyses from the pivotal trial evaluating Zykadia(TM) (ceritinib) in ALK+ non-small cell lung cancer (NSCLC), overall survival results from the pivotal trial of the mTOR inhibitor Afinitor(R) (everolimus) in advanced ...
MarketWatch - Tue, 16 Sep 2014 22:17

Novartis to present cancer drug data at ESMO 2014
Zenopa - Wed, 17 Sep 2014 04:07

3SBio enters licence pact with JenKem Technology to develop and market PEG ...
3SBio Inc., (3SBio), a leading biotechnology company based in China focussing on researching, developing, manufacturing and marketing bio-pharmaceutical products, has entered into an exclusive licence agreement with JenKem Technology Co., Ltd ...
pharmabiz.com - Wed, 17 Sep 2014 23:22



Some Cancer Experts See 'Overdiagnosis,' Question Emphasis on Early Detection
Officials from five major dermatology societies have blasted the idea of calling non-melanoma skin cancers IDLEs, saying that deaths from squamous-cell cancers are rising and basal-cell carcinomas can invade surrounding tissues if untreated. "Renaming ...
Wall Street Journal - Sun, 14 Sep 2014 13:01



Update on Head and Neck Cancers, HPV: Creating public awareness
Human papillomavirus type 16 (HPV-16) is a major contributory factor in oropharyngeal squamous cell carcinoma (OPSCC). ... HPV is the leading cause of oropharyngeal cancers, and a very small number of front of the mouth, oral cavity cancers. HPV16 is ...
Dentistry IQ - Tue, 16 Sep 2014 08:33

The power of faith: Despite terminal illness, NC man isn't afraid
Enlarge. Tim and Terry Loftin pose for a photo with their grandson, Noah, at Myrtle Beach in October 2013. Tim Loftin has squamous cell carcinoma, an inoperable, terminal cancer that is the byproduct of third-degree burns he suffered in a 1979 work ...
Spartanburg Herald Journal - Tue, 16 Sep 2014 11:00



Connor's Corner
Buffalo Bills Hall-of-Fame quarterback Jim Kelly recently said he was cancer free after two long battles with squamous-cell carcinoma. The Buffalo ... Wilson allowed a small city filled with blue collar workers to invest in something greater than ...
Gannonknight - Wed, 17 Sep 2014 05:00

Novel Therapies with Potential to Be the Next Biotech Blockbuster
Telecommunication · Consumer Discretionary · Consumer Staples · Energy · Financials · Healthcare · Industrials · Materials · Technology · Utilities · Large/Mid Cap · Small/Micro Cap · Market Movers · ETFs/Funds ..... It was approved first for breast ...
Equities.com - Tue, 16 Sep 2014 00:05

Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex
Knockdown of Hhex increases proliferation rate in hepatocellular carcinoma cells, whereas Hhex expression cell-autonomously reduces cell proliferation rate in multiple cell lines by increasing G1 phase length through a c-Myc-dependent mechanism ...
Nature.com - Mon, 15 Sep 2014 02:58


<-   1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014